Janina Müller-Deile
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Janina Müller-Deile has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
- Mario Schiffer
Department of Nephrology and Hypertension, Uniklinikum Erlangen and Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany.
6 shared publications Hermann Haller
Department of Medicine/Nephrology, Hannover Medical School, Hannover, Germany
5 shared publicationsJan Fiedler
Institute of Molecular and Translational Therapeutic Strategies, Hannover Medical School, Hannover, Germany
2 shared publicationsJenny Nyström
Department of Physiology, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
2 shared publicationsThomas Thum
Institute of Molecular and Translational Therapeutic Strategies, Hannover Medical School, Hannover, Germany
2 shared publicationsAnke Schwarz
Division of Nephrology and Hypertension, Department of Medicine, Hannover Medical School, Hannover, Germany
1 shared publication
Latest Publications
- Open Access
- 26 February 2018
- Published by Springer Nature in Scientific Reports
- Vol. 8 (1) , 1-15
Overexpression of preeclampsia induced microRNA-26a-5p leads to proteinuria in zebrafish
So far the pathomechanism of preeclampsia in pregnancy is focussed on increased circulating levels of soluble fms-like tyrosin kinase-1 (sFLT-1) that neutralizes glomerular VEGF-A expression and prevents its signaling at the glomerular endothelium. As a result of changed glomerular VEGF-A levels endotheliosis and podocyte foot process effacement are typical morphological features of preeclampsia. Recently, microRNA-26a-5p (miR-26a-5p) was described to be also upregulated in the preeclamptic placenta. We found that miR-26a-5p targets VEGF-A expression by means of PIK3C2α in cultured human podocytes and that miR-26a-5p overexpression in zebrafish causes proteinuria, edema, glomerular endotheliosis and podocyte foot process effacement. Interestingly, recombinant zebrafish Vegf-Aa protein could rescue glomerular changes induced by miR-26a-5p. In a small pilot study, preeclamptic patients with podocyte damage identified by podocyturia, expressed significantly more urinary miR-26a-5p compared to healthy controls. Thus, functional and ultrastructural glomerular changes after miR-26a-5p overexpression can resemble the findings seen in preeclampsia and indicate a potential pathophysiological role of miR-26a-5p in addition to sFLT-1 in this disease.
- 26 February 2018
- Published by Springer Nature in Scientific Reports
- Vol. 8 (1) , 1-15
Open AccessOverexpression of preeclampsia induced microRNA-26a-5p leads to proteinuria in zebrafish
So far the pathomechanism of preeclampsia in pregnancy is focussed on increased circulating levels of soluble fms-like tyrosin kinase-1 (sFLT-1) that neutralizes glomerular VEGF-A expression and prevents its signaling at the glomerular endothelium. As a result of changed glomerular VEGF-A levels endotheliosis and podocyte foot process effacement are typical morphological features of preeclampsia. Recently, microRNA-26a-5p (miR-26a-5p) was described to be also upregulated in the preeclamptic placenta. We found that miR-26a-5p targets VEGF-A expression by means of PIK3C2α in cultured human podocytes and that miR-26a-5p overexpression in zebrafish causes proteinuria, edema, glomerular endotheliosis and podocyte foot process effacement. Interestingly, recombinant zebrafish Vegf-Aa protein could rescue glomerular changes induced by miR-26a-5p. In a small pilot study, preeclamptic patients with podocyte damage identified by podocyturia, expressed significantly more urinary miR-26a-5p compared to healthy controls. Thus, functional and ultrastructural glomerular changes after miR-26a-5p overexpression can resemble the findings seen in preeclampsia and indicate a potential pathophysiological role of miR-26a-5p in addition to sFLT-1 in this disease.
- Open Access
- 1 October 2017
- Published by Wolters Kluwer Health in Transplantation Direct
- Vol. 3 (10) , e210
Graft Growth and Podocyte Dedifferentiation in Donor-Recipient Size Mismatch Kidney Transplants
Background: Kidney transplantation is the treatment choice for patients with end-stage renal diseases. Because of good long-term outcome, pediatric kidney grafts are also accepted for transplantation in adult recipients despite a significant mismatch in body size and age between donor and recipient. These grafts show a remarkable ability of adaptation to the recipient body and increase in size in a very short period, presumably as an adaptation to hyperfiltration. Methods: We investigated renal graft growth as well as glomerular proliferation and differentiation markers Kiel-67, paired box gene 2 and Wilms tumor protein (WT1) expression in control biopsies from different transplant constellations: infant donor for infant recipient, infant donor for child recipient, infant donor for adult recipient, child donor for child recipient, child donor for adult recipient, and adult donor for an adult recipient. Results: We detected a significant increase in kidney graft size after transplantation in all conditions with a body size mismatch, which was most prominent when an infant donated for a child. Podocyte WT1 expression was comparable in different transplant conditions, whereas a significant increase in WT1 expression could be detected in parietal epithelial cells, when a kidney graft from a child was transplanted into an adult. In kidney grafts that were relatively small for the recipients, we could detect reexpression of podocyte paired box gene 2. Moreover, the proliferation marker Kiel-67 was expressed in glomerular cells in grafts that increased in size after transplantation. Conclusions: Kidney grafts rapidly adapt to the recipient size after transplantation if they are transplanted in a body size mismatch constellation. The increase in transplant size is accompanied by an upregulation of proliferation and dedifferentiation markers in podocytes. The different examined conditions exclude hormonal factors as the key trigger for this growth so that most likely hyperfiltration is the key trigger inducing the rapid growth response.
- 1 October 2017
- Published by Wolters Kluwer Health in Transplantation Direct
- Vol. 3 (10) , e210
Open AccessGraft Growth and Podocyte Dedifferentiation in Donor-Recipient Size Mismatch Kidney Transplants
Background: Kidney transplantation is the treatment choice for patients with end-stage renal diseases. Because of good long-term outcome, pediatric kidney grafts are also accepted for transplantation in adult recipients despite a significant mismatch in body size and age between donor and recipient. These grafts show a remarkable ability of adaptation to the recipient body and increase in size in a very short period, presumably as an adaptation to hyperfiltration. Methods: We investigated renal graft growth as well as glomerular proliferation and differentiation markers Kiel-67, paired box gene 2 and Wilms tumor protein (WT1) expression in control biopsies from different transplant constellations: infant donor for infant recipient, infant donor for child recipient, infant donor for adult recipient, child donor for child recipient, child donor for adult recipient, and adult donor for an adult recipient. Results: We detected a significant increase in kidney graft size after transplantation in all conditions with a body size mismatch, which was most prominent when an infant donated for a child. Podocyte WT1 expression was comparable in different transplant conditions, whereas a significant increase in WT1 expression could be detected in parietal epithelial cells, when a kidney graft from a child was transplanted into an adult. In kidney grafts that were relatively small for the recipients, we could detect reexpression of podocyte paired box gene 2. Moreover, the proliferation marker Kiel-67 was expressed in glomerular cells in grafts that increased in size after transplantation. Conclusions: Kidney grafts rapidly adapt to the recipient size after transplantation if they are transplanted in a body size mismatch constellation. The increase in transplant size is accompanied by an upregulation of proliferation and dedifferentiation markers in podocytes. The different examined conditions exclude hormonal factors as the key trigger for this growth so that most likely hyperfiltration is the key trigger inducing the rapid growth response.
- 1 October 2017
- Published by Elsevier in Kidney International
- Vol. 92 (4) , 836-849
Podocytes regulate the glomerular basement membrane protein nephronectin by means of miR-378a-3p in glomerular diseases
- 1 October 2017
- Published by Elsevier in Kidney International
- Vol. 92 (4) , 836-849
Podocytes regulate the glomerular basement membrane protein nephronectin by means of miR-378a-3p in glomerular diseases
- 16 May 2017
- Published by Springer Nature in Pflügers Archiv - European Journal of Physiology
- Vol. 469 (7-8) , 1007-1015
Podocytes from the diagnostic and therapeutic point of view
The central role of podocytes in glomerular diseases makes this cell type an interesting diagnostic tool as well as a therapeutic target. In this review, we discuss the current literature on the use of podocytes and podocyte-specific markers as non-invasive diagnostic tools in different glomerulopathies. Furthermore, we highlight the direct effects of drugs currently used to treat primary glomerular diseases and describe their direct cellular effects on podocytes. A new therapeutic potential is seen in drugs targeting the podocytic actin cytoskeleton which is essential for podocyte foot process structure and function. Incubation of cultured human podocyte cell lines with sera from patients with active glomerular diseases is currently also used to identify novel circulating factors with pathophysiological relevance for the glomerular filtration barrier. In addition, treatment of detached urinary podocytes from patients with substances that restore their cytoskeleton might serve as a novel personalized tool to estimate their potential for podocyte recovery ex vivo.
- 16 May 2017
- Published by Springer Nature in Pflügers Archiv - European Journal of Physiology
- Vol. 469 (7-8) , 1007-1015
Podocytes from the diagnostic and therapeutic point of view
The central role of podocytes in glomerular diseases makes this cell type an interesting diagnostic tool as well as a therapeutic target. In this review, we discuss the current literature on the use of podocytes and podocyte-specific markers as non-invasive diagnostic tools in different glomerulopathies. Furthermore, we highlight the direct effects of drugs currently used to treat primary glomerular diseases and describe their direct cellular effects on podocytes. A new therapeutic potential is seen in drugs targeting the podocytic actin cytoskeleton which is essential for podocyte foot process structure and function. Incubation of cultured human podocyte cell lines with sera from patients with active glomerular diseases is currently also used to identify novel circulating factors with pathophysiological relevance for the glomerular filtration barrier. In addition, treatment of detached urinary podocytes from patients with substances that restore their cytoskeleton might serve as a novel personalized tool to estimate their potential for podocyte recovery ex vivo.
- Open Access
- 1 November 2016
- Published by AME Publishing Company in Annals of Translational Medicine
- Vol. 4 (21) , 439
Drugs targeting dynamin can restore cytoskeleton and focal contact alterations of urinary podocytes derived from patients with nephrotic syndrome
Drugs targeting dynamin can restore cytoskeleton and focal contact alterations of urinary podocytes derived from patients with nephrotic syndrome
- 1 November 2016
- Published by AME Publishing Company in Annals of Translational Medicine
- Vol. 4 (21) , 439
Open AccessDrugs targeting dynamin can restore cytoskeleton and focal contact alterations of urinary podocytes derived from patients with nephrotic syndrome
Drugs targeting dynamin can restore cytoskeleton and focal contact alterations of urinary podocytes derived from patients with nephrotic syndrome
- 9 November 2015
- Published by Wiley in European Journal of Clinical Investigation
- Vol. 45 (12) , 1260-1269
A new rescue regimen with plasma exchange and rituximab in high‐risk membranous glomerulonephritis
Even though current treatment guidelines for idiopathic membranous glomerulonephritis (iMGN) exist, many questions regarding an optimal therapy remain unanswered. Complete remission cannot be achieved in all patients; relapses occur, in some cases frequently, and side effects from the immunosuppressive therapy are common. Therapeutic options in high-risk patients not responding to standard immunosuppressive therapies are limited. Recent research reveals that the human M-type phospholipase A2 receptor (PLA2R) is a causative factor in iMGN that parallels clinical disease activity. However, in some patients, this correlation is not evident and additional undetermined factors seem to play a role. We evaluated a new rescue protocol including plasma exchanges (PE) against albumin, intravenous immunoglobulins (IVIGs) and rituximab for 10 patients with a biopsy-proven diagnosis of iMGN who were therapy-resistant to all conventional regimens and had a urinary protein to creatinine ratio of more than 10 000 mg/g Crea. We compared this protocol with standard immunosuppressive protocols including monthly alternating prednisolone plus cyclophosphamide (18 patients), cyclosporine plus prednisolone (23 patients) and rituximab alone (eight patients) in a retrospective design. Our rescue regimen with PE, IVIGs and rituximab achieved partial remission in 90% of patients who had been otherwise refractory to therapy. The mean time to partial remission was 2·1 months. Furthermore, two anti-PLA2R-antibody negative patients were also treated with this rescue regimen, achieving partial remission after 1 and 4 months. A combination of PE, IVIGs and rituximab is a treatment option to consider for high-risk patients with iMGN who are refractory to conventional therapy.
- 9 November 2015
- Published by Wiley in European Journal of Clinical Investigation
- Vol. 45 (12) , 1260-1269
A new rescue regimen with plasma exchange and rituximab in high‐risk membranous glomerulonephritis
Even though current treatment guidelines for idiopathic membranous glomerulonephritis (iMGN) exist, many questions regarding an optimal therapy remain unanswered. Complete remission cannot be achieved in all patients; relapses occur, in some cases frequently, and side effects from the immunosuppressive therapy are common. Therapeutic options in high-risk patients not responding to standard immunosuppressive therapies are limited. Recent research reveals that the human M-type phospholipase A2 receptor (PLA2R) is a causative factor in iMGN that parallels clinical disease activity. However, in some patients, this correlation is not evident and additional undetermined factors seem to play a role. We evaluated a new rescue protocol including plasma exchanges (PE) against albumin, intravenous immunoglobulins (IVIGs) and rituximab for 10 patients with a biopsy-proven diagnosis of iMGN who were therapy-resistant to all conventional regimens and had a urinary protein to creatinine ratio of more than 10 000 mg/g Crea. We compared this protocol with standard immunosuppressive protocols including monthly alternating prednisolone plus cyclophosphamide (18 patients), cyclosporine plus prednisolone (23 patients) and rituximab alone (eight patients) in a retrospective design. Our rescue regimen with PE, IVIGs and rituximab achieved partial remission in 90% of patients who had been otherwise refractory to therapy. The mean time to partial remission was 2·1 months. Furthermore, two anti-PLA2R-antibody negative patients were also treated with this rescue regimen, achieving partial remission after 1 and 4 months. A combination of PE, IVIGs and rituximab is a treatment option to consider for high-risk patients with iMGN who are refractory to conventional therapy.
- Open Access
- 1 January 2013
- Published by Dustri-Verlag Dr. Karl Feistle in Clinical Nephrology – Case Studies
- Vol. 2013 (1) , 1-4
Thromboembolism in renal transplant artery due to atrial fibrillation
Central and peripheral arterial thromboembolisms are well known complications of atrial fibrillation. We report the first case of thromboembolism in a renal transplant due to atrial fibrillation after changing anticoagulation treatment. A 79-year-old woman who had undergone kidney transplantation in 2001 presented herself with abdominal pain and oliguria. Serum creatinine had been stable (130 - 150 µmol/l) since transplantation, and, because of atrial fibrillation, the patient received oral anticoagulation treatment for many years until it was switched to aspirin 100 mg due to a cholecystectomy in 2012. Three weeks thereafter is when the patient was admitted to our unit. In a computed tomography scan of the abdomen, multiple renal infarcts were detected. The thromboembolism resulted in a complete loss of transplant function. As the patient remained anuric, the transplant was declared to be lost, immunosuppression was reduced, and renal replacement therapy was commenced over a central catheter. However, the patient died the next day. Our case highlights the fact that changing anticoagulation treatment should be performed carefully and can be detrimental. The location of thromboembolism in renal transplant artery makes this case unique and has not ever been described thus far. As renal transplantation and risk factors for thromboembolism i.e., atrial fibrillation are increasing, embolization in renal transplant artery is a potential reason for abdominal pain and anuria; physicians should take this into consideration when treating transplanted patients.
- 1 January 2013
- Published by Dustri-Verlag Dr. Karl Feistle in Clinical Nephrology – Case Studies
- Vol. 2013 (1) , 1-4
Open AccessThromboembolism in renal transplant artery due to atrial fibrillation
Central and peripheral arterial thromboembolisms are well known complications of atrial fibrillation. We report the first case of thromboembolism in a renal transplant due to atrial fibrillation after changing anticoagulation treatment. A 79-year-old woman who had undergone kidney transplantation in 2001 presented herself with abdominal pain and oliguria. Serum creatinine had been stable (130 - 150 µmol/l) since transplantation, and, because of atrial fibrillation, the patient received oral anticoagulation treatment for many years until it was switched to aspirin 100 mg due to a cholecystectomy in 2012. Three weeks thereafter is when the patient was admitted to our unit. In a computed tomography scan of the abdomen, multiple renal infarcts were detected. The thromboembolism resulted in a complete loss of transplant function. As the patient remained anuric, the transplant was declared to be lost, immunosuppression was reduced, and renal replacement therapy was commenced over a central catheter. However, the patient died the next day. Our case highlights the fact that changing anticoagulation treatment should be performed carefully and can be detrimental. The location of thromboembolism in renal transplant artery makes this case unique and has not ever been described thus far. As renal transplantation and risk factors for thromboembolism i.e., atrial fibrillation are increasing, embolization in renal transplant artery is a potential reason for abdominal pain and anuria; physicians should take this into consideration when treating transplanted patients.